BIVSX Fees and Costs — Invenomic Fund, Super Institutional Class
Data updated: 2026-09-28
The net expense ratio is 2.80%: a 1.74% management fee plus 1.07% other expenses, less a 0.02% fee waiver. There are no sales loads or redemption fees. In fiscal 2025 the fund paid $4.6M in broker commissions, 0.4382% of average net assets, and portfolio turnover was 197%.
BIVSX Fees and Expenses
Annual operating expenses and sales charges of BIVSX. Prospectus, as of March 2, 2026.
| Annual operating expenses | |
|---|---|
| Management fee | 1.74% |
| 12b-1 fee | 0.00% |
| Other expenses | 1.07% |
| Gross expense ratio | 2.82% |
| Fee waiver | −0.02% |
| Net expense ratio | 2.80% |
| Sales charges | |
|---|---|
| Max front load | 0.00% |
| Max deferred load | 0.00% |
| Redemption fee | — |
| Expense limitation in place (N-CEN) | Yes |
| Fees waived or reduced during the year | No |
| Waived fees subject to recoupment | No |
BIVSX Costs Over Time
On $10,000 invested in BIVSX, assuming 5% a year before costs, total costs come to $1,937 over 5 years, cutting the return by 3.40% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Fund expenses (net expense ratio 2.80%) | $294 | $896 | $1,518 |
| Trading costs (broker commissions) | $46 | $140 | $238 |
| Lost growth on money paid in costs | $0 | $52 | $182 |
| Total costs | $340 | $1,089 | $1,937 |
| Value after costs | $10,160 | $10,488 | $10,826 |
| Impact on return, per year | 3.40% | 3.40% | 3.40% |
BIVSX Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending October 31, 2025.
- Explicit cost rate (commissions ÷ average net assets): 0.4382%
- Total broker commissions: $4.6M
- Bought from dealers (principal trades, not a cost): $3.6M
- Portfolio turnover (prospectus): 197%
- Securities lending: none during the year
BIVSX Agency Brokers
Commissions paid.
| Broker | Amount | Share |
|---|---|---|
| MAREX CAPITAL MARKETS INC. | $4.6M | 99.66% |
| UBS Securities LLC | $16K | 0.34% |
BIVSX Dealer Counterparties
Securities bought directly from dealers (principal trades).
| Broker | Amount | Share |
|---|---|---|
| MAREX CAPITAL MARKETS INC. | $3.6M | 100.00% |
Invenomic Fund Share Classes
Net expense ratio and maximum front-end load of each share class, cheapest first.
| Ticker | Class | Net expense ratio | Front load |
|---|---|---|---|
| BIVSX | Super Institutional Class | 2.80% | none |
| BIVIX | Institutional Class | 3.05% | none |
| BIVRX | Investor Class | 3.30% | none |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.